Skip to main content
    N

    Neuraxis, Inc. (NRXS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $7.78
    +1.25 (+19.14%)

    Market Cap: $82.00M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    27%(3/11)
    Avg Surprise
    -208.56%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.21 - $-0.21
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.12-82.6%
    60d ago$-0.12-82.6%
    30d ago$-0.210.0%
    7d ago$-0.210.0%
    Current$-0.21
    Revenue Consensus
    $2M
    Range$2M - $2M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.04
    1 analysts
    Revenue Consensus
    $3M
    Range$3M - $3M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.04---
    Sep 26EST
    		-$-0.21---
    Jun 26
    Reported Aug 11
    		$-0.19$-0.32+40.63%Beat+13.6%
    Mar 26
    Reported May 12
    		$-0.18$-0.24+25.75%Beat+46.0%
    Dec 25
    Reported Mar 19
    		$-0.10N/A+52.38%Beat+51.2%
    Sep 25
    Reported Nov 10
    		$-0.24$-0.20-20.00%Miss+4.4%
    Jun 25
    Reported Aug 12
    		$-0.22$-0.19-15.79%Miss+47.8%
    Mar 25
    Reported May 12
    		$-0.33$-0.24-37.50%Miss-3.1%
    Dec 24
    Reported Mar 20
    		$-0.20$0.04-612.50%Miss+19.5%
    Sep 24
    Reported Nov 12
    		$-0.25$0.00N/ABeat+81.4%
    Jun 24
    Reported Aug 9
    		$-0.42$-0.05-743.20%Miss+65.2%
    Mar 24
    Reported Apr 9
    		$-0.32$-0.10-220.00%Miss+15.8%
    Dec 23
    Reported Feb 28
    		$-0.25$-0.15-69.80%Miss-
    Sep 23
    Reported Nov 20
    		$-1.35$-0.17-694.12%Miss-
    Jun 23
    Reported Aug 11
    		$-1.21$0.00N/AMiss-
    Mar 23
    Reported May 31
    		$-0.38$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-10.99EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-144.40%Operating Margin-110.20%
    ROE-139.80%ROIC-88.28%
    Financial Health
    Debt/Equity0.01xInterest Coverage-72.63x
    Current Ratio3.04xQuick Ratio2.95x
    Trading Statistics
    Beta1.36Avg Volume206.40K
    52-Week High$9.3352-Week Low$2.21

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.91
    SMA 20$7.17
    SMA 50$6.60
    SMA 200$6.51
    EMA 10$6.99
    EMA 20$6.94
    EMA 50$6.80
    EMA 200$6.15

    MACD

    Line: 0.09Signal: 0.12Hist: -0.03

    ADX

    ADX: 21.5+DI: 27.3-DI: 22.4

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down8.0
    PSAR$7.85

    Bollinger Bands

    Upper Band$7.98
    Lower Band$6.37
    %B Position2247%(Upper)
    Band Width0.88

    RSI (14-Day)

    Neutral
    63.1

    Momentum Oscillators

    Stoch %K39.6
    Stoch %D22.5
    Williams %R-13.2
    ROC (10d)8.5%
    Momentum0.61
    CCI (20d)55.3
    MFI (14d)62.7

    Volatility Measures

    ATR (14d)$0.54(6.9%)
    StdDev (20d)0.40
    Hist Vol86.7%(High)

    Volume Flow

    VWAP$7.46
    OBV88.5M
    AD Line-71.8M
    CMF (20d)0.241

    Volume Metrics

    Avg Vol (20d)147.4K
    Vol Ratio7.6x(High)
    VWMA (20d)$7.41

    Pivot Points

    R3$7.41
    R2$7.02
    R1$6.78
    Pivot Point$6.39
    S1$6.14
    S2$5.75
    S3$5.51

    Advanced Oscillators

    TSI6.08
    Ultimate Osc59.3
    KST101.44

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.93M$1.61M$968,127$811,414$894,086$895,655$761,165$666,625$611,500$646,635$531,458$477,460
    Cost of Revenue$272,573$218,366$141,311$135,487$146,643$139,475$116,413$97,050$73,458$75,081$72,345$67,287
    Gross Profit$1.66M$1.39M$826,816$675,927$747,443$756,180$644,752$569,575$538,042$571,554$459,113$410,173
    Operating Expenses$3.78M$3.13M$2.54M$2.78M$2.47M$3.05M$2.11M$2.22M$2.74M$2.40M$2.09M$3.43M
    R&D$274,344$99,567$243,886$130,850$115,197$117,867$247,485$126,247$54,312$5,570$-2,221$44,950
    SG&A$3.51M$3.03M$2.30M$2.65M$2.35M$2.93M$1.86M$2.09M$2.69M$2.40M$2.09M$3.39M
    Operating Income$-2,124,712$-1,740,679$-1,716,867$-2,100,085$-1,717,858$-2,295,098$-1,466,592$-1,651,273$-2,206,832$-1,832,120$-1,628,341$-3,022,339
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$2,103
    Interest Expense$19,794$26,189$28,637$29,661$13,434$2,237$2,394$105,564$144,514$48,243$17,399$6.21M
    Income Before Tax$-2,085,746$-1,761,432$-1,708,657$-2,122,796$-1,690,418$-2,278,684$-1,447,906$-1,755,234$-2,917,710$-2,120,651$-1,592,296$-8,625,363
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,085,746$-1,761,432$-1,708,657$-2,122,796$-1,690,418$-2,278,684$-1,447,906$-1,755,234$-2,917,710$-2,120,651$-1,592,296$-8,625,363
    EBITDA$-2,049,301$-1,718,926$-1,655,965$-2,076,930$-1,664,099$-2,270,091$-1,438,661$-1,599,510$-2,698,409$-2,039,988$-1,562,359$-1,073,479
    EBIT$-2,065,952$-1,735,243$-1,680,020$-2,093,135$-1,676,984$-2,276,447$-1,445,512$-1,649,670$-2,773,196$-2,072,408$-1,572,794$-2,414,739
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NRXS

    Government Contracts

    Gov Obligations (TTM)
    $63000
    Gov Obligations / Revenue
    N/A
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    11.8 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    An ear-stimulating treatment for gut pain now has coverage reaching over 147 million people.

    NeurAxis (NRXS) has expanded medical policy coverage for its ear-stimulating treatment, PENFS (IB-Stim), adding approximately 26 million lives from a national health insurer. This expansion brings the total national...

    Stock Titan•10/15/26•Bullish

    NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives

    NeurAxis, Inc. announced a significant medical policy coverage expansion from a major national health insurer, adding approximately 26 million covered lives for its Percutaneous Electrical Nerve Field Stimulation (PENFS)...

    The Manila Times•10/15/26•Bullish

    NeurAxis Announces Major National Insurer Coverage Expansion for IB-Stim Penetrating 26 Million Medical Plan Members

    NeurAxis, Inc. announced expanded medical policy coverage for its IB-Stim device, which treats functional abdominal pain associated with IBS and functional dyspepsia in patients aged 8 and older. This new coverage from...

    Quiver Quantitative•10/15/26•Bullish

    Neuraxis Inc (NRXS) CEO Brian Carrico Buys 268 Shares as Stock T

    Neuraxis Inc's CEO, Brian Carrico, purchased 268 shares of the company, bringing his total holdings to 227,604 shares. This transaction is part of a larger trend of insider buying at Neuraxis...

    GuruFocus•10/9/26•Somewhat-Bullish

    Neuraxis Executive Thomas Carrico Acquires 328 Shares at $4.84 Each

    Thomas Joseph Carrico, Neuraxis's Chief Revenue, Compliance, and Product Officer, recently purchased 328 shares of Neuraxis common stock at $4.84 each on October 8...

    Kalkine Media•10/8/26•Somewhat-Bullish

    NRXS Valuation and Fair Value

    P/E
    -11.0x
    P/B
    14.0x
    See GNG's fair value

    NRXS Profitability: Margins, ROIC and FCF

    Gross margin
    85.6%
    Operating margin
    -110.2%
    Net margin
    -144.4%
    ROIC
    -88.3%
    ROE
    -139.8%
    FCF margin
    -106.0%

    NRXS Competitors

    CompanyTicker
    Equillium IncEQ
    Sera Prognostics IncSERA
    Forian IncFORA
    Cardiff Oncology IncCRDF
    Rallybio CorpRLYB
    Lixte Biotechnology Holdings IncLIXT
    Hyperfine IncHYPR
    Kazia Therapeutics Ltd ADRKZIA

    Sector: Healthcare

    NRXS Bull Case vs Bear Case

    Bull case

    • NRXS grew quarterly revenue 115.7% year over year.

    Bear case

    • NRXS has a -144.4% net profit margin.
    • NRXS beat EPS estimates in 37.5% of its last 8 reported quarters.

    NRXS Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -81.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.21
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About NRXS

    Does NRXS pay dividends?

    Neuraxis, Inc. (NRXS) does not currently pay a regular dividend.

    What is NRXS's market cap?

    Neuraxis, Inc. (NRXS) has a market capitalization of $82.00M with a current stock price of $7.78.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In